EP #174 | Inspirational quotes by Charlie Munger and what we learned from it | & AbbVie's acquisition and Pfizer's withdrawal of weight-loss drug

Dec 2, 2023

In this podcast, the hosts explore the wisdom of Charlie Munger and its relevance to dividend investing and wealth-building strategies. They discuss AbbVie's acquisition of ImmunoGen and Pfizer's withdrawal of a weight-loss drug. The main topics include continuous learning, patience in investing, humility, and the power of reading. Listener questions cover potential disagreements between the hosts, initiating positions with slightly down share prices, and the future of Berkshire Hathaway. The podcast also touches on positive mindset, learning from others' mistakes, the future of Berkshire Hathaway, and Chevron's correction.

Ask episode

Chapters

Transcript

Episode notes

Introduction

00:00 • 2min

AbbVie's Acquisition of Muno Gen

02:11 • 15min

The Legacy and Longevity of Charlie Munger

17:19 • 22min

39:39 • 3min

Foolish Mistakes and Learning from Others' Mistakes

42:48 • 5min

Differing Opinions on Dividend Topics

48:01 • 2min

The Future of Berkshire Hathaway and Investing Strategies

49:55 • 17min

Analysis of Chevron's correction and opinion on Scorpio tankers

01:07:21 • 4min

Welcome to Episode 174 of the Dividend Talk Podcast! In this episode, titled "The Best of Charlie Munger Quotes," your hosts EMF and European DGI explore the timeless wisdom of Charlie Munger. They delve into Munger's insightful quotes, discussing their relevance to dividend investing and wealth-building strategies and what it personally meant to them.

In the news segment, EMF shares his thoughts on AbbVie's $10.1 billion deal to acquire ImmunoGen, including the cancer drug ELAHERE. The acquisition is set to strengthen AbbVie's position in treating ovarian cancer and solid tumors, with the deal expected to finalize in mid-2024.

eDGI discusses Pfizer and shares his thoughts on when it may finally become attractive, considering its $30 billion additional debt due to the Seagen acquisition and the recent withdrawal of its weight-loss drug.

The main topic centers on Charlie Munger's quotes, exploring concepts such as the value of continuous learning, patience in investing, the importance of humility, and the power of reading to generate ideas.

In the listener questions segment, Simon Stott asks about potential disagreements between EMF and EDGI, and speculates on the future of Berkshire Hathaway's share price and dividend policy after the passing of its iconic leaders.

Andrew Stoddart inquires about initiating starting positions with companies when their share prices are slightly down, especially in the context of dividend kings/aristocrats.

The Dividend Growth Quest features a discussion on the consideration of fees in dividend investing, while MH79 raises questions about the WisdomTree Global Quality Dividend Growth UCITS ETF - USD.

The hosts tackle questions about the Federal Reserve's dovish stance, the sustainability of dividend growth, the significance of free cash flow yield in valuation, and the post-correction outlook for Chevron. Adrian Fastinger also shares his opinion on Scorpio Tankers (STNG), a company engaged in aggressive debt reduction and buybacks, with a growing dividend.

Join the Dividend Talk community as they explore these intriguing topics and share valuable insights for dividend investors.